Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 15/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 14/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 12/20 | 1.00 |
| ▸ | CDK2 | P24941 | 5/20 | 0.63 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.63 |
| ▸ | CDK4 | P11802 | 2/20 | 0.63 |
| ▸ | CCND1 | P24385 | 2/20 | 0.63 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.63 |
| ▸ | CDK9 | P50750 | 2/20 | 0.63 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.63 |
| ▸ | CCNK | O75909 | 3/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.53 |
| ▸ | CDK7 | P50613 | 3/20 | 0.53 |
| ▸ | CCNH | P51946 | 3/20 | 0.53 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.53 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16802780 | 1.00 | MAPK8 (1.00) | MAPK8MAPK10MAPK9CDK2CCNT1 | |
| SCHEMBL16802595 | 0.89 | MAPK8 (1.00) | MAPK8MAPK10MAPK9CDK2CCNT1 | |
| SCHEMBL16802770 | 0.88 | MAPK8 (1.00) | MAPK8MAPK10MAPK9CDK2CCNT1 | |
| SCHEMBL16802577 | 0.88 | MAPK8 (1.00) | MAPK8MAPK10MAPK9CDK2CCNT1 | |
| SCHEMBL18148264 | 0.88 | MAPK8 (1.00) | MAPK8MAPK10MAPK9CDK2CCNT1 | |
| SCHEMBL16802705 | 0.88 | MAPK8 (1.00) | MAPK8MAPK10MAPK9CDK2CCNT1 | |
| SCHEMBL18148248 | 0.88 | MAPK8 (1.00) | MAPK8MAPK10MAPK9CDK2CCNT1 | |
| SCHEMBL16802782 | 0.88 | MAPK8 (1.00) | MAPK8MAPK10MAPK9CDK2CCNT1 | |
| SCHEMBL16802773 | 0.86 | MAPK8 (1.00) | MAPK8MAPK10MAPK9CDK2CCNT1 | |
| SCHEMBL18148253 | 0.86 | MAPK8 (1.00) | MAPK8MAPK10MAPK9CDK2CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062911-A1 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, AND/OR AMELIORATING CHEMOTHERAPY-INDUCED PREMATURE OVARIAN FAILURE (POF) | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-03-02 | — | — | US | disclosed |
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062911-A1 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, AND/OR AMELIORATING CHEMOTHERAPY-INDUCED PREMATURE OVARIAN FAILURE (POF) | POF1B, MAPKAPK2, MAPKAPK3 | MAPK8 23/4885MAPK10 10/4885MAPK9 47/4885 |
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | MAPK3, MAP3K3, MAP3K2 | MAPK8 55/4885MAPK10 31/4885MAPK9 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.